10 Best Quality Stocks To Watch Right Now

Cisco Systems Inc. (NASDAQ: CSCO) is involved in yet another internal restructuring of sorts, and the company has done what it can to manage its shares higher and higher. In fact, shares were up a sharp 28% year-to-date before Thursday. Now a new wave of networking coverage from Credit Suisse is casting a dark shadow on Cisco, and the implication is that shares could fall some 15%, if the thesis turns out to be accurate.

Credit Suisse initiated new coverage on shares of Cisco with a very unambitious Underperform rating. The firm issued a $21.00 price target, versus a $24.80 closing price on Wednesday.

Analyst Kulbinder Garcha believes that software-defined networking is going to be a threat to the traditional networking giants. He still thinks that Cisco is a high-quality company, but it also may�be the most vulnerable of the old oligarchy. His biggest concern is that software-defined networking will shrink gross margins, even as Cisco tries to increase its services in the revenue mix.

10 Best Quality Stocks To Watch Right Now: Powershares Water Resource Portfolio (PHO)

PowerShares Water Resources Portfolio (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Palisades Water Index (the Index). The Palisades Water Index includes water companies drawn from sectors, which include water utilities, treatment, analytical and monitoring, infrastructure and distribution, water resource management, and conglomerate water companies. The Index includes companies that focus on the provision of potable water, the treatment of water and the technology and services that are directly related to water consumption. The Palisades Water Index was created by Hydrogen Ventures, LLC.

The Fund will normally invest at least 80% of its total assets in American depositary receipts (ADRs) and common stocks of companies in the water industry. For purposes of this 80% policy, a company will be considered to be in the water industry if at least 50% of its revenues come from water-related activities. The Fund will normally invest at least 90% of its total assets in ADRs and common stocks that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate the performance of the Index. The Fund generally will invest in the stocks comprising the Index in proportion to their weightings in the Index. The Fund�� investment advisor is PowerShares Capital Management LLC.

Advisors' Opinion:

• [By Todd Shriber, ETF Professor]

  Unusual volume (at least 5X ADV): iShares Utilities ETF (NYSE: IDU), First Trust Utilities AlphaDEX Fund (NYSE: FXU), iShares MSCI Germany Small Cap ETF (NYSE: EWGS), iShares MSCI USA ETF (NYSE: EUSA), SPDR S&P Emerging Europe ETF (NYSE: GUR), PowerShares Water Resources (NYSE: PHO) and the Vanguard Industrials ETF (NYSE: VIS).

10 Best Quality Stocks To Watch Right Now: Nestle SA (NESN)

Nestle SA is a Swiss Company engaged in the nutrition, health and wellness sectors. It is the holding company of the Nestle Group, which comprises subsidiaries, associated companies and joint ventures throughout the world. It has such business units as Food and Beverage, Nestle Waters and Nestle Nutrition. It is also active in the pharmaceutical sector. It divides its products into Powdered and liquid beverages, Water, Milk products and Ice cream, Nutrition, Prepared dishes and cooking aids, Confectionery, PetCare and Pharmaceutical products. In February 2011, the Company acquired CM&D Pharma Ltd. Advisors' Opinion:

• [By Corinne Gretler]

  Swiss stocks fell for a second day, their first back-to-back losses this month, as Nestle (NESN) SA retreated after reporting slower growth in sales.

Top Industrial Disributor Stocks To Own For 2015: Immunomedics Inc.(IMMU)

Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. The company?s products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study completed product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib/II clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. Its early phase clinical trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug conjugate therapy. The com pany also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers. In addition, it markets and sells a diagnostic product, LeukoScan, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. Immunomedics, Inc. has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd., to develop vaccines against cancers that include melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Advisors' Opinion:

• [By George Budwell]

  Immunomedics (NASDAQ: IMMU  ) develops monoclonal antibodies for the treatment of cancer, autoimmune disorders, and other life-threatening diseases. The company has six products in clinical trials for a variety of diseases. Shares of Immunomedics have fallen hard and fast since the company announced the termination of a licensing deal with Takeda Pharmaceutical over veltuzumab last month. Even positive clinical trial results for 90-Y clivatuzumab, a treatment for advanced pancreatic cancer, failed to slow the fall. And last week, the pace of the decline picked up to the tune of a 15% drop on heavy volume.

• [By Wallace Witkowski]

  Immunomedics Inc. (IMMU) �shares rose 19% to $6.18 on heavy volume after the small cap biotech said it just started treating patients with its pancreatic cancer drug in a late-stage clinical trial.

10 Best Quality Stocks To Watch Right Now: D.R. Horton Inc.(DHI)

D.R. Horton, Inc. operates as a homebuilding company in the United States. The company?s Homebuilding segment engages in the acquisition and development of land, and construction and sale of residential homes on the land in 26 states and 72 markets in the United States primarily under the name of D.R. Horton and America?s Builder. This segment also builds traditional single-family detached homes, as well as attached homes, such as town homes, duplexes, triplexes and condominiums, which share common walls and roofs. Its Financial Services segment involves in originating and selling mortgages, as well as provides title insurance policies, examination, and closing services to homebuyers. The company markets and sells its homes through commissioned employees and independent real estate brokers. The company was founded in 1978 and is based in Fort Worth, Texas.

Advisors' Opinion:

• [By John Maxfield]

  Sometimes, the most important data about a company is the hardest to come by. In this case, I'm referring to historic sales figures from�D.R. Horton (NYSE: DHI  ) , the nation's largest homebuilder by units sold. While this is the single-most accurate reflection of D.R. Horton's performance -- not to mention, it provides valuable insight into the condition of the overall housing market -- a comprehensive data set containing the figures is nowhere to be found.

10 Best Quality Stocks To Watch Right Now: Arca Biopharma Inc.(ABIO)

ARCA biopharma, Inc., a biopharmaceutical company, engages in the development of genetically-targeted therapies for cardiovascular diseases. Its principal product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure and also for the prevention of atrial fibrillation in patients with heart failure. The company has identified common genetic variations in the cardiovascular system that it believes interact with Gencaro?s pharmacology and may predict patient response. ARCA has collaboration with Laboratory Corporation of America to develop the Gencaro Test, a companion test for the genetic markers that identify these common genetic variations. The company is headquartered in Broomfield, Colorado.

Advisors' Opinion:

• [By Ant贸nio Costa]
  Arca Biopharma Inc (NASDAQ: ABIO) OBV Indicator continues its uptrend showing investor interest. A restest of 1.8 seems very likely. Last week, Dawson James initiated coverage on shares with a buy rating and a $3.75 target price.

  During the day I tweet many times to my readers. I encourage everybody to subscribe AC Investor Blog twitter and newsletter, so you can receive my trade ideas and stock news in real time.

• [By Bryan Murphy]

  Were you listening back on December 20th when yours truly suggested Arca Biopharma Inc. (NASDAQ:ABIO) was a budding bullish play? I hope so. If you stepped in then, you'd now be up 9.3%. No, it's not a lot. Then again, it's been less than two weeks. Regardless of whether or not you got into ABIO then, though, as of today, Arca Biopharma have cleared a hurdle that suggests the best is yet to come.

• [By Bryan Murphy]

  I don't come hear to pat myself on the back, however. I come hear to let you know the same conditions that made American Community overbought and ripe for a reversal and suggested Real Goods Solar, Inc. was ready to rally are now saying - respectively - ParkerVision, Inc. (NASDAQ:PRKR) shares are due for a pullback and Arca Biopharma Inc. (NASDAQ:ABIO) is on the verge of a big bullish thrust.

• [By Bryan Murphy]

  Congratulations if you were in a GW Pharmaceuticals PLC (NASDAQ:GWPH) position anytime before today's open. Now get out. Not only is the party over for GWPH, there's something better you could do with your money now. It's a not-so-obscure-any-longer biotech called Arca Biopharma Inc. (NASDAQ:ABIO), and though the stock's up pretty nicely since two Fridays ago, ABIO is also just getting started.

10 Best Quality Stocks To Watch Right Now: First Trust Global Wind Energy (FAN)

First Trust ISE Global Wind Energy Index Fund is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, of an equity index called the ISE Global Wind Energy Index. The Fund will normally invest at least 90% of its net assets (plus the amount of any borrowings for investment purposes) in common stocks that comprise the Index or in depositary receipts that may include American depositary receipts (ADRs), global depositary receipts (GDRs), European depositary receipts (EDRs) or other depositary receipts (collectively, Depositary Receipts) representing securities in the Index. The Fund invests in sectors, which include Consumer Discretionary, Energy, Industrials, Materials and Utilities. First Trust Advisors L.P. (First Trust) is the Investment Advisor of the Fund. Advisors' Opinion:

• [By John Udovich]

  Small cap wind stock Broadwind Energy Inc (NASDAQ: BWEN) is up 203.7% since the start of the year, but investors might want to contain their excitement when they look closer at the�stock and�consider its�long term performance along with the performance of other wind investments like First Trust Global Wind Energy ETF (NYSEARCA: FAN) and wind energy stocks Vestas Wind Systems (OTCMKTS: VWDRY) and China Ming Yang Wind Power Group Ltd (NYSE: MY) to see whether BWEN is just blowing more hot air.

10 Best Quality Stocks To Watch Right Now: ProShares UltraShort S&P500 (SDS)

ProShares UltraShort S&P500 (the Fund), formerly UltraShort S&P500 ProShares, seeks daily investment results that correspond to twice the inverse daily performance of the S&P 500 Index. The S&P 500 Index is a measure of large-cap United States stock market performance. The S&P 500 Index is a capitalization-weighted index of 500 United States operating companies and real estate investment trusts (REITs) selected by an S&P committee through a non-mechanical process that factors criteria, such as liquidity, price, market capitalization, financial viability and public float.

The S&P 500 Index is a price return index. Reconstitution of the Index occurs both on a quarterly and on an ongoing basis. The Fund takes positions in securities and/or financial instruments that, in combination, should have similar daily return characteristics as 200% of the daily return of the index. The Fund�� investment advisor is ProShare Advisors LLC.

Advisors' Opinion:

• [By John Udovich]

  The so-called Hindenburg Omen predicting a major market crash is increasingly popping into the headlines; but regardless of whether or not you believe in the prophecy,�short ETFs like ProShares UltraShort S&P500 ETF (NYSEARCA: SDS), ProShares Short Dow30 ETF (NYSEARCA: DOG) and�ProShares UltraShort QQQ ETF (NYSEARCA: QID) can off you some protection or insurance. We have also periodically added short ETFs to our�SmallCap Network Elite Opportunity (SCN EO) portfolio as a�hedge against short-term�market downturns or�short-term trend reversals and right now, we have the ProShares UltraShort S&P500 ETF in our portfolio.

10 Best Quality Stocks To Watch Right Now: Hudson Global Inc (HSON)

Hudson Global, Inc. (Hudson) incorporated on January 1, 2003, provides specialized professional-level recruitment and related talent solutions worldwide. The Company's Core service offerings include Permanent Recruitment, Contract Consulting, Legal eDiscovery, Recruitment Process Outsourcing (RPO) and Talent Management solutions. As of December 31, 2012, the Company operated in 20 countries with three geographic business segments: Hudson Americas, Hudson Asia Pacific, and Hudson Europe. The Company's core service offerings include Permanent Recruitment, Contract Consulting, Legal eDiscovery,RPO and Talent Management Solutions.

The Company's Permanent Recruitment services leverage the firm's more than 1,200 consultants, supported by the Company's psychologists and other scientific specialists in the development and delivery of its methods to identify, select and engage the best-fit talent for critical client roles. In Contract Consulting, Hudson provides a range of project management, interim management and professional contract staffing services. Hudson's Legal eDiscovery services consists of eDiscovery solutions, managed document review including logistical deployment, project management, process design and productivity management, and contract attorney staffing. Hudson's RPO delivers outsourced recruitment solutions tailored to the individual needs of mid- to large-cap multinational companies. Hudson RPO services include complete recruitment outsourcing, project-based outsourcing, contingent workforce solutions and recruitment consulting. Hudson's Talent Management Solutions capability encompasses services such as talent assessment, interview training, executive coaching, employee development and outplacement.

The Company's clients include small to large-sized corporations and government agencies. As of December 31, 2012 , there were approximately 460 Hudson Americas clients, 1,200 Hudson Asia Pacific clients and 2,700 Hudson Europe clients.

Advisors' Opinion:

• [By John Udovich]

  Staffing 360 Solutions Inc. Having a consolidation strategy that is well suited for the highly fragmented temporary staffing industry, small cap Staffing 360 Solutions intends to become a major international publicly-held staffing organization with diversified staffing services by engaging in a targeted accretive acquisition strategy. Staffing 360 Solutions has already developed a significant pipeline of acquisition targets in the IT, financial, accounting, healthcare and banking industries. Moreover, its executive chairman Brendan Flood spent seven years at Hudson Global Inc (NASDAQ: HSON) in various roles in Europe and the United States, culminating with him leading the company's IPO and listing of its common stock on the Nasdaq National Market in 2003. During 2004 and 2005 he was the CFO/COO for Hudson North America (returning the business to profitability after several loss-making years) while�prior to the IPO, it should be noted that Hudson was part of what is now Monster Worldwide, Inc (NYSE: MWW). CEO Matt Briand also has 17 years of staffing industry experience from various recruitment, sales, management and executive roles. On Wednesday, Staffing 360 Solutions issued an updated forecast for the next three fiscal quarters is as follows: $24.1 million for the quarter ending May 31, 2014, $30.2 million for the quarter ending August 31, 2014, and $32.1 million for the quarter ending November 30, 2014. Staffing 360 Solutions has also recently completed the acquisition of�PeopleSERVE, which�provides IT professional and management consultants on a contract and direct hire basis to state and local government, multinational and regional businesses and entrepreneurial firms throughout the greater Boston area.�On Wednesday, Staffing 360 Solutions fell 0.50% to $1.99 (STAF has a 52 week trading range of $0.55 to $2.10 a share) for a market cap of $60.98 million plus the stock is down 0.5% since the start of the year, up 20.6% over the past year and up 165.3% ove

10 Best Quality Stocks To Watch Right Now: AstraZeneca PLC (AZN)

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.

Cardiovascular

The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.

Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.

The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.

Gastrointestinal

AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.

Infection

The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.

Neuroscience

AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).

Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.

Oncology

AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.

Advisors' Opinion:

• [By WWW.DAILYFINANCE.COM]

  www.take2games.com Sometimes, the right answer when a potential suitor appears before you on bended knee is "Yes." But there's been no shortage of attractive offers getting spurned on Wall Street. Sometimes those offers just don't make sense: Boards aren't ready to sell; shareholders think their stock is worth more, and vote down the deals. AstraZeneca (AZN) recently became the latest big company to refuse a suitor's advances. Pharmaceutical giant Pfizer (PFE) was shot down last week after making a $117 billion offer for AstraZeneca. Pfizer claims that was its final offer; apparently, it wasn't enough. Sometimes, those disinterested companies are better off on their own. However, for every Facebook (FB) that correctly scoffed at a large figure (offered $1 billion, it's worth north of $150 billion today), there are many companies that lived to regret turning down. Here are five companies whose owners really should have taken the money and run. Circuit City Circuit City is gone. The consumer electronics superstore chain filed for bankruptcy, liquidating all of its stores in 2009. It didn't have to go out that way. There was no shortage of companies proposing to take over the once-vibrant retailer. It turned down private equity firms that wanted to pay $8 a share in 2003 and then $17 a share in 2005. Blockbuster Video -- yes, that Blockbuster -- even started to make buyout overtures in 2008. Blockbuster was hoping that teaming up with Circuit City would create "an $18 billion retail enterprise uniquely positioned for the convergence of media content and electronic devices." It never panned out. Circuit City was out of business less than a year later. Take-Two Interactive (TTWO) Weeks before Take-Two Interactive's "Grand Theft Auto IV" hit stores in 2008, Electronic Arts (EA) initiated a hostile takeover. It offered to pay $26 a share for Take-Two, but with the game expected to set industry sales records (which it eventually did), there was little reason

10 Best Quality Stocks To Watch Right Now: Waste Management Inc.(WM)

Waste Management, Inc., through its subsidiaries, provides waste management services to residential, commercial, industrial, and municipal customers in North America. It offers collection, transfer, recycling, and disposal services. The company also owns, develops, and operates waste-to-energy and landfill gas-to-energy facilities in the United States. Its collection services involves in picking up and transporting waste and recyclable materials from where it was generated to a transfer station, material recovery facility, or disposal site; and recycling operations include collection and materials processing, plastics materials recycling, and commodities recycling. In addition, it provides recycling brokerage, which includes managing the marketing of recyclable materials for third parties; and electronic recycling services, such as collection, sorting, and disassembling of discarded computers, communications equipment, and other electronic equipment. Further, the company e ngages in renting and servicing portable restroom facilities to municipalities and commercial customers under the Port-o-Let name; and involves in landfill gas-to-energy operations comprising recovering and processing the methane gas produced naturally by landfills into a renewable energy source, as well as provides street and parking lot sweeping services. Additionally, it offers portable self-storage, fluorescent lamp recycling, and medical waste services for healthcare facilities, pharmacies, and individuals, as well as provides services on behalf of third parties to construct waste facilities. The company was formerly known as USA Waste Services, Inc. and changed its name to Waste Management, Inc. in 1998. Waste Management, Inc. was incorporated in 1987 and is based in Houston, Texas.

Advisors' Opinion:

• [By Dividends4Life]

  Related Articles:
  - Meredith Corp. (MDP) Dividend Stock Analysis
  - Target Corporation (TGT) Dividend Stock Analysis
  - Waste Management, Inc. (WM) Dividend Stock Analysis
  - Coca-Cola Company (KO) Dividend Stock Analysis
  - More Stock Analysis

• [By Arjun Sreekumar]

  For instance, Waste Management (NYSE: WM  ) has amassed a fleet of around 2,000 trucks that are powered by compressed natural gas and plans to add more, while UPS (NYSE: UPS  ) recently announced plans to purchase 285 more gas-powered trucks next year.

• [By Wallace Witkowski]

  Some of the companies most dependent on government for revenue are Harris Corp. (HRS) �with 80% of revenue government-derived; Granite Construction Inc. (GVA) �with 58%; Flir Systems Inc. (FLIR) �with 54%; and Waste Management Inc. (WM) � and Republic Services Inc. (RSG) �both with 50%, according to Goldman Sachs.